Saturday 17 October 2026
Export MGX’s income statement to Excel — free account
Metagenomi Therapeutics, Inc.
In the quarter to June 2026, revenue fell 103.0%, EPS fell 35.2% and free cash flow grew 7.98%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.78
0.07
−8.24%
Follow MGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 2 | 2 | 2 |
| (40.87%) | (44.67%) | (49.02%) | (60.61%) | ||
| (29.27%) | (32.20%) | (34.71%) | (41.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.96%) | (56.73%) | (64.47%) | (87.57%) | |
Average Days of Receivables |
11.34 | 4.42 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.47) | (2.40) | (2.33) | (2.28) | |
Free Cash Flow |
(92.41) | (89.43) | (87.50) | (85.80) | |
Capital Expenditures |
(0.79) | (0.54) | (0.27) | (0.31) | |
| Other line items | |||||
Cash ROIC |
(25.49%) | (28.00%) | (31.48%) | (36.79%) | |
Accounts Receivable Turnover |
39.91 | 32.28 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
310.86% | 374.59% | 396.72% | 653.31% | |
Selling, General and Administrative Expense of Revenue |
87.62% | 106.27% | 118.76% | 188.27% | |
Share Based Compensation of Revenue |
40.67% | 47.02% | 51.39% | 77.60% | |
Operating CF/Net income |
1.03 | 1.01 | 1.02 | 0.91 | |
Depreciation/Fixed assets |
0.10 | 0.17 | 0.25 | 0.40 | |
Capex/Depreciation |
(0.58) | (0.26) | (0.10) | (0.08) | |
Revenue per Share |
0.83 | 0.68 | 0.59 | 0.36 | |
Operating CF per Share |
(2.45) | (2.39) | (2.32) | (2.27) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.02 |
Columns are period end dates